Nanjing Hicin Pharmaceutical Co., Ltd.

SZSE:300584 Stock Report

Market Cap: CN¥2.7b

Nanjing Hicin Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Nanjing Hicin Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

There's Reason For Concern Over Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Massive 28% Price Jump

Aug 15
There's Reason For Concern Over Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Massive 28% Price Jump

We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve

May 01
We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve

Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 29% Price Boost Is Out Of Tune With Revenues

Mar 08
Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 29% Price Boost Is Out Of Tune With Revenues

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nanjing Hicin Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:300584 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202450042-6848N/A
6/30/202449342-10054N/A
3/31/202450537-174-1N/A
12/31/202351836-17324N/A
9/30/202352535-16667N/A
6/30/202352034-17935N/A
3/31/202349332-14664N/A
1/1/202352632-225-6N/A
9/30/2022504278-182-26N/A
6/30/2022529282-157-10N/A
3/31/2022567285-1402N/A
1/1/2022578286-3460N/A
9/30/202161235-2562N/A
6/30/2021647402498N/A
3/31/20217025212101N/A
12/31/202070655-4773N/A
9/30/202078868-1197N/A
6/30/202084581-2482N/A
3/31/202088092887N/A
12/31/2019925975497N/A
9/30/2019871982975N/A
6/30/2019826952176N/A
3/31/201975989268N/A
12/31/201871283177N/A
9/30/201867982-3251N/A
6/30/201862477N/A47N/A
3/31/201854375N/A57N/A
12/31/201745566N/A47N/A
9/30/201738860N/A69N/A
6/30/201733353N/A59N/A
3/31/201730548N/A44N/A
12/31/201628145N/A38N/A
9/30/201626248N/A44N/A
12/31/201522140N/A54N/A
12/31/201419834N/A24N/A
12/31/201317033N/A45N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 300584's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 300584's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 300584's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 300584's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 300584's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 300584's Return on Equity is forecast to be high in 3 years time


Discover growth companies